Canadian Biomarker Integration Network for Depression Study

Summary

This study is a pilot to assess feasibility of the protocol in patients and controls across six participating sites. The goal is to identify biological markers (biomarkers)that can be measured at baseline or early in treatment to predict treatment outcome in individual patients with Major Depressive Disorder (MDD). Biomarkers of interest will be clinical (using interview and self-report measures), molecular (from blood samples) and neurobiological (using neuroimaging and EEG).

Conditions

• Major Depressive Disorder

Interventions

DRUG

escitalopram

Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.

DRUG

aripiprazole

At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.

Sponsors & Collaborators

• University of Toronto

  collaborator OTHER

• University of Calgary

  collaborator OTHER

• University of British Columbia

  collaborator OTHER

• McGill University

  collaborator OTHER

• Queen's University

  collaborator OTHER

• Centre for Addiction and Mental Health

  collaborator OTHER

• McMaster University

  collaborator OTHER

• University Health Network, Toronto

  lead OTHER

Principal Investigators

• Sidney Kennedy, MD · University Health Network, University of Toronto

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

FACTORIAL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2012-04-23

Primary Completion

2017-01-31

Completion

2017-01-31

Countries

• Canada

Study Locations